Skip to main content

Table 11 Effects of Glucomedix® on systolic blood pressure in hypertensive rats induced by L-NAME

From: GlucoMedix®, an extract of Stevia rebaudiana and Uncaria tomentosa, reduces hyperglycemia, hyperlipidemia, and hypertension in rat models without toxicity: a treatment for metabolic syndrome

Group/dose (mg/kg)

Time (days)

0 days

7 days

14 days

21 days

28 days

NT

110.6 ± 1.13

109.9 ± 1.21

110.4 ± 0.79

110.6 ± 0.79

110.0 ± 1.29

LN

111.6 ± 0.98

152.4 ± 2.37**

162.1 ± 2.54**

171.3 ± 1.80 **

178.9 ± 2.19 **

LN + Enal 25

112.6 ± 0.98

118.4 ± 0.98*++

120.7 ± 0.95*++

123.3 ± 1.11 *++

116.9 ± 1.57 *++

LN + GM 250

113.1 ± 0.90

155.4 ± 2.15**

142.9 ± 5.70**+

139.6 ± 3.95**+

154.0 ± 1.15 **+

LN + GM 500

115.3 ± 0.76

155.0 ± 1.91**

143.9 ± 2.12**+

147.4 ± 1.51**+

137.7 ± 2.29 **++

LN + GM 1000

116.1 ± 1.07

140.9 ± 5.79**

145.0 ± 6.58**+

144.6 ± 2.23**+

123.7 ± 1.11 *++

  1. Values are expressed as mean ± SD. n = 7; NT = normotensive control; LN = L-NAME induced control; LN + Enal = Enalapril; LN + GM 250, LN + GM 500 and LN + GM 1000 = GlucoMedix at 250, 500 and 1000 mg/kg respectively. * p < 0.05, ** p < 0.001 compared to normotensive control group; +p < 0.05, ++p < 0.001 compared to L-NAME (LN) induced control group
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us